Great summary BDZ!

I especially like this:

"The trial here is going to be called BETonMACE. And as I mentioned all of the packaging and the CMC (chemistry, manufacturing and control), and the organizing the clinics, the PIs (principal investigators), doing the safety reviews, that’s already completed and we are moving forward with this trial quite quickly. The patient population will be patients with low HDL, below 40 (mg/dL), that’s where about 70% of the cardio events take place. And they will have diabetes. All of the patients this time. We will still be testing both Rosuvastatin and Atorvastatin as a request by the agencies. But it’s really designed to show that the one does work better than the other, and that will allow us to move forward in the future with a fixed-dose combination with the superior one, which we do believe is Rosuvastatin."